University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Laura J. van 't Veer, PhD

Laura J. van 't Veer, PhD

Leader, Breast Oncology Program, and Director, Applied Genomics, UCSF Helen Diller Family Comprehensive Cancer Center
Angela and Shu Kai Chan Endowed Chair in Cancer Research

Cancer Center Program Memberships

Breast Oncology | Cancer Genetics

Research Summary

I am a world-renowned Molecular Biologist, and Leader of the Breast Oncology Program and Associate Director Applied Genomics at the HDFCCC. I am the former Head of Diagnostic Oncology of the Netherlands Cancer Institute, and inventor of MammaPrint. My research focuses on personalized medicine, and aims to advance patient management based on knowledge of the genetic makeup of the tumor as well as the genetic makeup of the patient. My laboratory at UCSF has a strong research line investigating human kinases and studies how kinase inhibitors elicit response and resistance. I am the UCSF Precision Medicine Platform convener for cancer. I chair the Biomolecular Committee of the I-SPY 2 trial ensuring CLIA compliant companion diagnostics. I am the Principal Investigator of the Athena Breast Health Network at UCSF, a 150,000-women cohort study evaluating new paradigms to enhance breast health for which I lead the targeted genome testing for 65,000 women for nine breast cancer susceptibility genes and a selection of ~100 known susceptibility Single Nucleotide Polymorphisms (SNPs). I am one of the PIs for the NIH Big Data to Knowledge Center on Genomics, facilitating worldwide standardization of sharing annotated genomics data. My role as chair of the AACR Diagnostic Policy committee and chair of the Scientific Advisory Committee of the National Biomarker Development Alliance underscores my lead role in this area.

Education

University of Amsterdam, Amsterdam, Netherlands, BSc, 1976-80, Biology, Molecular Oncology
University of Amsterdam, Amsterdam, Netherlands, MSc,1980-84, Experimental Oncology
University of Leiden, Leiden, Netherlands, PhD, 1984-89, Medicine, Oncogene Activation and Tumorigenesis


Professional Experience

  • 1989-1991
    Postdoctoral Fellow, Cancer Center, Harvard Medical School and Massachusetts General Hospital, Boston
  • 1992-1993
    Postdoctoral Fellow, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute
  • 1993-2010
    Molecular Biologist, Department of Pathology, Division of Experimental Therapy, The Netherlands Cancer Institute
  • 1993-2010
    Group Leader, Molecular Pathology, Department of Pathology, Division of Experimental Therapy, The Netherlands Cancer Institute
  • 1993-2005
    Head DNA, Diagnostic Laboratories, Molecular Pathology, The Netherlands Cancer Institute
  • 1993-2005
    Head DNA, Diagnostic Laboratory, Family Cancer Clinic, The Netherlands Cancer Institute
  • 1997-2003
    Head, Family Cancer Clinic, The Netherlands Cancer Institute
  • 2002-2010
    Honorary Staff Member, Department of Surgery, Leiden University Medical Center, The Netherlands
  • 2004-2007
    Chief Operating Officer, Agendia BV, Amsterdam
  • 2007-2013
    Chief Research Officer, Agendia BV, Amsterdam
  • 2007-2010
    Clinical Division Head (ad interim), Division of Diagnostic Oncology, Clinical Departments of Pathology, Radiology, Nuclear Medicine, Clinical Chemistry, Family Cancer Clinic, The Netherlands Institute
  • 2008-2010
    Research Department Head, Department of Experimental Therapy (includes Molecular Pathology), The Netherlands Institute
  • 2008-2010
    Visiting Associate Professor, Cancer Center, University of California, San Francisco
  • 2010
    Visiting Associate Professor, Department of Pathology, University of California, San Francisco
  • 2010
    Visiting Associate Professor, Department of Radiology, University of California, San Francisco
  • 2010
    HS Clinical Instructor, Department of Laboratory Medicine, University of California, San Francisco
  • 2010-present
    Associate Director, Cancer Center, University of California, San Francisco
  • 2010-present
    Director, Applied Genomics, Cancer Center, University of California, San Francisco
  • 2010-present
    Professor, Department of Laboratory Medicine, University of California, San Francisco
  • 2010-present
    Professor, Department of Pathology, University of California, San Francisco
  • 2010-present
    Professor, Department of Radiology, University of California, San Francisco
  • 2011-present
    Faculty Member, Biomedical Sciences Graduate Program, University of California, San Francisco
  • 2011-present
    Faculty Member, Pharmaceutical Sciences and Pharmacogenomics Medicine, Clinical Chemistry, Family Cancer Clinic, University of California, San Francisco
  • 2011-present
    Angela and Shu Kai Chan Endowed Chair in Cancer Research, Department of Laboratory Medicine, University of California, San Francisco

Honors & Awards

  • 2005
    IARC Medal of Honor, Lyon, France
  • 2006
    Van der Scheuren award lecture for European Breast Cancer Research, EBCC5
  • 2007
    ESMO Lifetime Achievement Award for Translational Research in Breast Cancer
  • 2007, 2008
    Breast Cancer Research Fund (BCRF-Pink Ribbon US) grant award
  • 2009
    First Annual Harry and Edith Gladstein Award, Indiana University, School of Medicine
  • 2012
    AACC Outstanding Speaker Award
  • 2014
    Second Prize, European Union Prize for Women Innovators
  • 2015
    European Inventor Award, European Patent Office
  • 2017
    European Cancer Organization (ECCO) Clinical Research Award

Selected Publications

  1. Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L. Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. Breast Cancer Res. 2017 Sep 11; 19(1):107.
    View on PubMed
  2. Severson TM, Wolf DM, Yau C, Peeters J, Wehkam D, Schouten PC, Chin SF, Majewski IJ, Michaut M, Bosma A, Pereira B, Bismeijer T, Wessels L, Caldas C, Bernards R, Simon IM, Glas AM, Linn S, van 't Veer L. The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting. Breast Cancer Res. 2017 Aug 25; 19(1):99.
    View on PubMed
  3. van 't Veer LJ, Yau C, Yu NY, Benz CC, Nordenskjöld B, Fornander T, Stål O, Esserman LJ, Lindström LS. Tamoxifen therapy benefit for patients with 70-gene signature high and low risk. Breast Cancer Res Treat. 2017 Aug 04.
    View on PubMed
  4. Schmidt MK, van den Broek AJ, Tollenaar RA, Smit VT, Westenend PJ, Brinkhuis M, Oosterhuis WJ, Wesseling J, Janssen-Heijnen ML, Jobsen JJ, Jager A, Voogd AC, van Leeuwen FE, van 't Veer LJ. Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women. J Natl Cancer Inst. 2017 08 01; 109(8).
    View on PubMed
  5. Engelhardt EG, van den Broek AJ, Linn SC, Wishart GC, Rutgers EJT, van de Velde AO, Smit VTHBM, Voogd AC, Siesling S, Brinkhuis M, Seynaeve C, Westenend PJ, Stiggelbout AM, Tollenaar RAEM, van Leeuwen FE, van 't Veer LJ, Ravdin PM, Pharaoh PDP, Schmidt MK. Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years. Eur J Cancer. 2017 Jun; 78:37-44.
    View on PubMed
  6. Ju YS, Martincorena I, Gerstung M, Petljak M, Alexandrov LB, Rahbari R, Wedge DC, Davies HR, Ramakrishna M, Fullam A, Martin S, Alder C, Patel N, Gamble S, O'Meara S, Giri DD, Sauer T, Pinder SE, Purdie CA, Borg Å, Stunnenberg H, van de Vijver M, Tan BK, Caldas C, Tutt A, Ueno NT, van 't Veer LJ, Martens JW, Sotiriou C, Knappskog S, Span PN, Lakhani SR, Eyfjörd JE, Børresen-Dale AL, Richardson A, Thompson AM, Viari A, Hurles ME, Nik-Zainal S, Campbell PJ, Stratton MR. Somatic mutations reveal asymmetric cellular dynamics in the early human embryo. Nature. 2017 03 30; 543(7647):714-718.
    View on PubMed
  7. Crawford B, Adams SB, Sittler T, van den Akker J, Chan S, Leitner O, Ryan L, Gil E, van 't Veer L. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients. Breast Cancer Res Treat. 2017 Jun; 163(2):383-390.
    View on PubMed
  8. Beumer IJ, Persoon M, Witteveen A, Dreezen C, Chin SF, Sammut SJ, Snel M, Caldas C, Linn S, van 't Veer LJ, Bernards R, Glas AM. Prognostic Value of MammaPrint® in Invasive Lobular Breast Cancer. Biomark Insights. 2016; 11:139-146.
    View on PubMed
  9. Abubakar M, Orr N, Daley F, Coulson P, Ali HR, Blows F, Benitez J, Milne R, Brenner H, Stegmaier C, Mannermaa A, Chang-Claude J, Rudolph A, Sinn P, Couch FJ, Devilee P, Tollenaar RA, Seynaeve C, Figueroa J, Sherman ME, Lissowska J, Hewitt S, Eccles D, Hooning MJ, Hollestelle A, Martens JW, van Deurzen CH, Investigators K, Bolla MK, Wang Q, Jones M, Schoemaker M, Wesseling J, van Leeuwen FE, Van 't Veer L, Easton D, Swerdlow AJ, Dowsett M, Pharoah PD, Schmidt MK, Garcia-Closas M. Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. Breast Cancer Res. 2016 Oct 18; 18(1):104.
    View on PubMed
  10. Cardoso F, Van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 2016 Aug 25; 375(8):717-729.
    View on PubMed
  11. Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 7; 375(1):23-34.
    View on PubMed
  12. Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 Jul 7; 375(1):11-22.
    View on PubMed
  13. Beumer I, Witteveen A, Delahaye L, Wehkamp D, Snel M, Dreezen C, Zheng J, Floore A, Brink G, Chan B, Linn S, Bernards R, van 't Veer L, Glas A. Equivalence of MammaPrint array types in clinical trials and diagnostics. Breast Cancer Res Treat. 2016 Apr; 156(2):279-87.
    View on PubMed
  14. Olow A, Chen Z, Niedner RH, Wolf DM, Yau C, Pankov A, Lee EP, Brown-Swigart L, van 't Veer LJ, Coppé JP. An Atlas of the Human Kinome Reveals the Mutational Landscape Underlying Dysregulated Phosphorylation Cascades in Cancer. Cancer Res. 2016 Apr 1; 76(7):1733-45.
    View on PubMed
  15. van den Broek AJ, van 't Veer LJ, Hooning MJ, Cornelissen S, Broeks A, Rutgers EJ, Smit VT, Cornelisse CJ, van Beek M, Janssen-Heijnen ML, Seynaeve C, Westenend PJ, Jobsen JJ, Siesling S, Tollenaar RA, van Leeuwen FE, Schmidt MK. Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers. J Clin Oncol. 2016 Feb 10; 34(5):409-18.
    View on PubMed
  16. Magbanua MJ, Wolf DM, Yau C, Davis SE, Crothers J, Au A, Haqq CM, Livasy C, Rugo HS. Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response. Breast Cancer Res. 2015; 17:73.
    View on PubMed
  17. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol. 2016 May; 141(2):386-401.
    View on PubMed
  18. Curl P, Vujic I, van 't Veer LJ, Ortiz-Urda S, Kahn JG. Correction: Cost-Effectiveness Of Treatment Strategies for BRAF-Mutated Metastatic Melanoma. PLoS One. 2015; 10(4):e0126988.
    View on PubMed
  19. van den Broek AJ, Schmidt MK, van 't Veer LJ, Tollenaar RA, van Leeuwen FE. Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: what's the evidence? A systematic review with meta-analysis. PLoS One. 2015; 10(3):e0120189.
    View on PubMed
  20. Lang JE, Scott JH, Wolf DM, Novak P, Punj V, Magbanua MJ, Zhu W, Mineyev N, Haqq CM, Crothers JR, Esserman LJ, Tripathy D, van 't Veer L, Park JW. Expression profiling of circulating tumor cells in metastatic breast cancer. Breast Cancer Res Treat. 2015 Jan; 149(1):121-31.
    View on PubMed

Go to UCSF Profiles, powered by CTSI